PRAX News and Press, Praxis Precision Medicines Inc. From 12/05/25

2025-12-05 09:06:32 ET from Deutsche Bank issued a price target of $303.00 for PRAX on 2025-12-05 13:37:32. The adjusted price target was set to $303.00. At the time of the announcement, PRAX was trading at $264.87. The overall price target consensus is at $338.86 with h...

2025-12-05 08:06:36 ET from Wedbush issued a price target of $83.00 for PRAX on 2025-12-05 12:43:26. The adjusted price target was set to $83.00. At the time of the announcement, PRAX was trading at $189.97. The overall price target consensus is at $369.00 with high pric...

2025-12-05 06:15:06 ET H.C. Wainwright analyst issues BUY recommendation for PRAX on December 5, 2025 11:06AM ET. The previous analyst recommendation was Buy. PRAX was trading at $189.97 at issue of the analyst recommendation. The overall analyst consensus : BUY. Cur...

Successful interim analysis triggered early stop for efficacy Topline study results to be shared at the American Epilepsy Society Annual Meeting on December 6, 2025 Praxis confirms an upcoming meeting with the FDA to discuss the results and NDA path BOSTON, Dec. 04, 20...

BOSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition ...

2025-11-26 15:57:40 ET The last time I spoke about Praxis Precision Medicines, Inc. ( PRAX ) it was in a Seeking Alpha article entitled "Positive 8-Week Radiant Study Data Leads To Other Expected Catalysts." In essence, I spoke about the company's development of its sodium c...

2025-11-24 20:23:25 ET Praxis Precision Medicines, Inc. (PRAX) Discusses Essential3 Program and Statistical Modeling Approaches in Clinical Studies November 24, 2025 1:00 PM EST... Read the full article on Seeking Alpha For further details see: Praxis Precision Medicines, In...

BOSTON, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into therapies for central nervous system (CNS) disorders driven by neuronal excitation-inhibition imbalance, today announced they wil...

2025-11-21 20:33:25 ET Praxis Precision Medicines, Inc. (PRAX) Jefferies London Healthcare Conference 2025 November 18, 2025 8:30 AM EST... Read the full article on Seeking Alpha For further details see: Praxis Precision Medicines, Inc. (PRAX) Presents at Jefferies London He...

2025-11-20 11:17:58 ET More on Praxis Precision Medicines Praxis: Back From The Dead, Ulixacaltamide Returns In Essential Tremor With Caveats Praxis Precision Medicines, Inc. (PRAX) Discusses Essential3 Topline Results and Next Steps in Essential Tremor Program Transcript ...